TrialJournal for immunotherapy of cancer2021

Trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund's adjuvant, cyclophosphamide, and polyICLC (Mel63).

Craig L Slingluff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.